ESMO WCGIC 2023 | Updates in adjuvant and neoadjuvant treatment for colon cancer
John Marshall, MD, PhD, Lombardi Comprehensive Cancer Center, Georgetown University, WA, provides an overview of the management of colon cancer in the adjuvant and neoadjuvant settings. The use of circulating tumor DNA (ctDNA) to assess minimal residual disease (MRD) in the adjuvant setting has shown great promise, and neoadjuvant preoperative therapy is additionally an emerging strategy. Prof. Marshall also highlights single cell testing in colon cancer. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
Yeah, it’s really a remarkable change that’s going on in the world of adjuvant and neoadjuvant treatment for colon cancer. In the adjuvant setting, the biggest story is around ctDNA minimal residual disease testing and how to incorporate that into decision making both prospective trials and experiential studies in the US. We’re incorporating it very quickly, but are we doing the right thing? So more data being presented in the neoadjuvant approach...
Yeah, it’s really a remarkable change that’s going on in the world of adjuvant and neoadjuvant treatment for colon cancer. In the adjuvant setting, the biggest story is around ctDNA minimal residual disease testing and how to incorporate that into decision making both prospective trials and experiential studies in the US. We’re incorporating it very quickly, but are we doing the right thing? So more data being presented in the neoadjuvant approach. We’re taking lessons from rectal cancer and saying should we be giving preoperative treatment to patients and is there a benefit for that? So new data being presented in that space controversial frankly, in many ways. And then as part of that, we are seeing some new cool data on single cell testing. So you can take a single cell from the blood tumor cell and in fact determine what therapies we should be giving to patients. So outstanding lecture by one of our keynote speakers, Dr Sabine Tejpar.
Read more...
